



BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL

1 Test. 43 Targets. ~1 Hour.

GRAM-NEGATIVE BACTERIA

Acinetobacter calcoaceticus-baumannii complex
Bacteroides fragilis
 Enterobacterales
 Enterobacter cloacae complex
 Escherichia coli
 Klebsiella aerogenes
 Klebsiella oxytoca
 Klebsiella pneumoniae group
 Proteus spp.
 Salmonella spp.
 Serratia marcescens
Haemophilus influenzae
Neisseria meningitidis
Pseudomonas aeruginosa
Stenotrophomonas maltophilia

GRAM-POSITIVE BACTERIA

Enterococcus faecalis
Enterococcus faecium
Listeria monocytogenes
Staphylococcus spp.
 Staphylococcus aureus
 Staphylococcus epidermidis
 Staphylococcus lugdunensis
Streptococcus spp.
 Streptococcus agalactiae
 Streptococcus pneumoniae
 Streptococcus pyogenes

YEAST

Candida albicans
Candida auris
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis
Cryptococcus (*C. neoformans*/*C. gattii*)

ANTIMICROBIAL RESISTANCE GENES

Carbapenemases

IMP
 KPC
 OXA-48-like
 NDM
 VIM

Colistin Resistance

mcr-1

ESBL

CTX-M

Methicillin Resistance

mecA/C
mecA/C and MREJ (MRSA)

Vancomycin Resistance

vanA/B

Overall Performance: 99.0% sensitivity and 99.8% specificity¹

US FDA-cleared | CE₂₇₉₇

Fast. Easy. Comprehensive.

Syndromic testing provides a streamlined workflow and fast, comprehensive results.



Identify Polymicrobial and Fungal Infections

Polymicrobial and fungal infections have the highest mortality and account for greater than 20% of healthcare associated bloodstream infections.³ Detect these infections with an expanded panel menu that provides gram-positive bacteria, gram-negative bacteria, and yeast results in one comprehensive report.

Gram-stain Directed Non-Comprehensive Panels




Test 1



Test 2

BIOFIRE BCID2 Panel



One comprehensive
report

Shorten Time to Optimal Therapy

A local antibiogram together with fast syndromic testing and antimicrobial stewardship allows for timely and optimal patient treatment.^{4,5,6,*}



With the rapid detection of 10 antimicrobial resistance gene targets, including a new target for more specific identification of MRSA, the BIOFIRE® BCID2 Panel provides opportunities to improve patient care.⁷



Shorten Time to
Optimal Therapy⁶




Decrease Unnecessary
Antibiotic Use⁷

Panel Information

Storage Conditions: all kit components stored at room temperature (15-25 °C)

BIOFIRE BCID2 Panel Reagent Kit (30 Pouches): RFIT-ASY-0147



Scan the QR code
for more information.

Learn more about the BIOFIRE range of commercially-available panels for syndromic infectious disease diagnostics.



Contact Us

bioMérieux S.A.
69280 Marcy l'Etoile
France
Tel: +33 (0) 4 78 87 20 00
Fax: +33 (0) 4 78 87 20 90
biomerieux.com

Manufactured by:
BioFire Diagnostics, LLC
515 Colorow Drive
Salt Lake City, UT 84108 USA
Tel: +1-801-736-6354
biofiredx.com

References

1. Overall performance is the aggregate of the prospective, archived, and seeded data from the clinical studies. Data on file, BioFire Diagnostics.
2. MacVane S, et al. (2016) J Clin Microbiol. 54(10):2455.
3. Wisplinghoff H, et al. (2004) Clin Infect Dis. 39:309-317.
4. Pardo J, et al. (2016) Diag Microbiol Infect Dis. 84(2):159-164.
5. Southern T, et al. (2015) Diag Microbiol Infect Dis. 81(2):96-101.
6. Messacar K, et al. (2016) J Ped Infect Dis Soc. 6(3):267.
7. Sparks et al. (2021) Pathology.

* Data generated using previous versions of this product.

Product availability varies by country. Consult your bioMérieux representative.

Learn more: biomerieux.com

PIONEERING DIAGNOSTICS